Insulin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type and Geography

List of Tables

The insulin market is projected to grow from US$ 54,611.42 million in 2021 to US$ 111,213.73 million by 2028. It is expected to grow at a CAGR of 10.8 % from 2022 to 2028.

The increase in the incidence of diabetes and rapid technological developments in insulin delivery devices by major players is expected to bolster the insulin market in the years to come. Additionally, the regeneration of the diabetic pancreas with advanced transplants is likely to emerge as a significant future trend in the insulin market from 2022 to 2028. However, the risks associated with insulin delivery devices hamper the overall market growth.

In diabetic people, the pancreas does not produce enough insulin, or the body does not usually respond to the insulin, increasing the blood glucose level. Insulin is a hormone that helps in lowering blood sugar levels. Insulin therapy is often an essential part of diabetes treatment. It is made by the beta cells of the pancreas and released into the blood when glucose levels rise, for example, after eating. Insulin helps glucose get into the body cells, which can be used for energy or stored for future use. Different types of insulin available vary in how quickly and for how long they can control blood sugar. Insulin does not come in pill form as the digestive system would break it down before it could work. Insulin therapy is exhausting; however, it is an effective way of lowering blood sugar levels.

Products with advanced insulin technology with more benefits are a major requirement in treating diabetes. There has been a rise in advancements in diabetes treatment over the past few years. As the prevalence of diabetes is increasing worldwide, the demand for advanced products is also boosting. The insulin market is expected to grow owing to an increase in the strategic efforts made by the industry players. The market players actively support their public and private research and academic institutes for increasing research activities.

A few of the recent developments related to rapid technological advancement in the insulin market are mentioned below:

In May 2022, Eli Lilly and Company received US FDA approval for its Mounjar (tirzepatide) once-weekly Glucose-Dependent Insulinotropic Polypeptide (GIP) and GLP-1 Glucagon-like Peptide-1 (GLP-1) receptor agonist for the treatment of adults with type 2 diabetes. The injection is decided to be available in 6 doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg) as an auto-injector pen with a preattached hidden needle.

In April 2022, Abbott partnered with CamDiab and Ypsomed to develop and commercialize an integrated automated insulin delivery (AID) system for around-the-clock diabetes management.

In October 2021, Tonghua Dongbao Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration (NMPA) for the clinical trial of its ultra-rapid-acting insulin lispro injection, BC Lispro. Currently, the drug is under phase III clinical trial in China.

In May 2021, Bigfoot Biomedical received 510(k) clearance by the US FDA for its Bigfoot Unity Diabetes Management System, which features connected smartpen caps that recommend insulin doses for people using multiple daily injections (MDI) therapy.

Thus, rapid technological advancements in insulin delivery devices are boosting the growth of the global insulin market.

The insulin market is bifurcated into type and geography. Based on type, the global insulin market is segmented into long-acting insulin, short-acting insulin & traditional human insulin, biosimilar insulin, pen & needle, rapid-acting insulin, concentrated insulin & combination insulin, glucagon-like-peptide-1 (GLP-1), pen & needle, and others. The long-acting insulin segment is estimated to account for the largest share during 2022-2028. Longer-acting insulin analogs are genetically engineered. Long-acting insulin analogs were initially developed to address the need of diabetics to maintain healthy blood sugar levels throughout the night. This insulin is slowly released into the circulation due to its acidic pH, causing it to precipitate when injected subcutaneously. Long-acting insulins are also called basal or background insulins. These long-acting insulins help in controlling blood sugar for a whole day. This is similar to how the pancreas produces insulin to maintain blood sugar levels between meals.

Opportunities in Insulin Market

The dominance of major players in developed countries, such as the US, has led to an increase in the global insulin market value. Novo Nordisk A/S, Elli Lily and Company, and Sanofi have a cumulative market revenue of over 90%. This is majorly credited to the evergreening of patents currently held by these dominating players. Additionally, the rising price of insulin in the US is estimated to boost the insulin market further. According to the Centers for Disease Control and Prevention, US$ 1 out of every US$ 4 in US health care costs is expended on diabetic patients.

Moreover, patients' lack of trust in biosimilar drugs is significantly propelling the insulin market. The shortage of biosimilar competition in the market-dominating region of North America is also expected to fuel the market growth. According to a study conducted by Health Action International (2019), Eli Lilly and Company, Novo Nordisk, and Sanofi are the only three manufacturers of insulin in the US, and they generate around 90% of revenue in the global market. In contrast, there are more than eight insulin manufacturers in Asia Pacific, according to the above study.

The World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Occupational Safety and Health Administration (OSHA), Food and Drug Administration (FDA), Centers for Personalized Medicine (CPM), and Organizations for Economic Co-operation and Development (OECD) are among the primary and secondary sources referred to while preparing the report on the insulin market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the insulin market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global insulin market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Product Code: TIPRE00004051

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Global Insulin Market - By Type
- 1.3.2 Global Insulin Market - By Geography

2. Insulin Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Insulin Market - Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 North America- PEST Analysis
- 4.2.2 Europe- PEST Analysis
- 4.2.3 Asia Pacific- PEST Analysis
- 4.2.4 Middle East & Africa- PEST Analysis
- 4.2.5 South & Central America- PEST Analysis
- 4.2.6 Expert Opinion

5. Insulin Market- Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Increase in Incidence of Diabetes
- 5.1.2 Rapid Technological Developments in Insulin Delivery Devices by Major Players
5.2 Market Restraints
- 5.2.1 Risks Associated with Insulin Delivery Devices
5.3 Market Opportunities
- 5.3.1 Insufficient Competition from Biosimilars
5.4 Future Trends
- 5.4.1 Regeneration of Diabetic Pancreas with Advanced Transplants
5.5 Impact Analysis

6. Insulin Market- Global Analysis

6.1 Global Insulin Market Revenue Forecast and Analysis
- 6.1.1 Global Insulin Market, By Geography - Forecast and Analysis
- 6.1.2 Global Insulin Market - Market Potential Analysis, By Region
6.2 Company Analysis
- 6.2.1 Market Positioning of Key Players
- 6.2.2 Comparative Company Analysis
- 6.2.3 Growth Strategy Analysis
- 6.2.4 Performance Of Key Players
  - 6.2.4.1 Novo Nordisk A/S
  - 6.2.4.2 Sanofi
  - 6.2.4.3 Eli Lily and Company
6.3 Customization Part
- 6.3.1 Market Share Analysis by Company
- 6.3.2 Market Share by Injectable GLPs

7. Insulin Market Analysis - By Type

7.1 Overview
7.2 Insulin Market Revenue Share, by Type (2021 and 2028)
7.3 Long Acting Insulin
- 7.3.1 Overview
- 7.3.2 Long Acting Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.3.2.1 Levemir
    - 7.3.2.1.1 Overview
    - 7.3.2.1.2 Levemir: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.3.2.2 Lantus
    - 7.3.2.2.1 Overview
    - 7.3.2.2.2 Lantus: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.3.2.3 Basaglar
    - 7.3.2.3.1 Overview
    - 7.3.2.3.2 Basaglar: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.3.2.4 Tresiba
    - 7.3.2.4.1 Overview
    - 7.3.2.4.2 Tresiba: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Rapid Acting Insulins
- 7.4.1 Overview
- 7.4.2 Rapid Acting Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.1 Novolog
    - 7.4.2.1.1 Overview
    - 7.4.2.1.2 Novolog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.2 Humalog
    - 7.4.2.2.1 Overview
    - 7.4.2.2.2 Humalog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.3 Admelog
    - 7.4.2.3.1 Overview
    - 7.4.2.3.2 Admelog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.4 Others
    - 7.4.2.4.1 Overview
    - 7.4.2.4.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.5 Short Acting Insulins and Traditional Human Insulins
- 7.5.1 Overview
- 7.5.2 Short Acting Insulins and Traditional Human Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.5.2.1 Novolin R
    - 7.5.2.1.1 Overview
    - 7.5.2.1.2 Novolin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.5.2.2 Humulin R
    - 7.5.2.2.1 Overview
    - 7.5.2.2.2 Humulin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.5.2.3 Insuman
    - 7.5.2.3.1 Overview
    - 7.5.2.3.2 Insuman: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.5.2.4 Others
    - 7.5.2.4.1 Overview
    - 7.5.2.4.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.6 Concentrated Insulins and Combination Insulins
- 7.6.1 Overview
- 7.6.2 Concentrated Insulins and Combination Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.6.2.1 NovoMix
    - 7.6.2.1.1 Overview
    - 7.6.2.1.2 NovoMix: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.6.2.2 Ryzodeg
    - 7.6.2.2.1 Overview
    - 7.6.2.2.2 Ryzodeg: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.6.2.3 Xultophy
    - 7.6.2.3.1 Overview
    - 7.6.2.3.2 Xultophy: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.6.2.4 Soliqua/Suliqua
    - 7.6.2.4.1 Overview
    - 7.6.2.4.2 Soliqua/Suliqua: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.7 Biosimilar Insulins
- 7.7.1 Overview
- 7.7.2 Biosimilar Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.7.2.1 Insulin Glargine
    - 7.7.2.1.1 Overview
    - 7.7.2.1.2 Insulin Glargine: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.7.2.2 Human Insulin
    - 7.7.2.2.1 Overview
    - 7.7.2.2.2 Human Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.8 Glucagon-like peptide-1 (GLP-1)
- 7.8.1 Overview
- 7.8.2 Glucagon-like peptide-1 (GLP-1): Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.9 Pens and Needles
- 7.9.1 Overview
- 7.9.2 Pens and Needles: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.10 Others
- 7.10.1 Overview
- 7.10.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)

8. Global Insulin Market - Geographic Analysis

8.1 North America: Insulin Market
- 8.1.1 Overview
- 8.1.2 North America: Insulin market - Revenue and Forecast to 2028 (US$ Million)
- 8.1.3 North America: Insulin Market, By Type, 2019-2028 (US$ Million)
  - 8.1.3.1 North America: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
  - 8.1.3.2 North America: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
  - 8.1.3.3 North America: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
  - 8.1.3.4 North America: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
  - 8.1.3.5 North America: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
- 8.1.4 North America: Insulin Market, by Country, 2021 & 2028 (%)
  - 8.1.4.1 US: Global Insulin market - Revenue and Forecast to 2028 (US$ Million)
    - 8.1.4.1.1 US: Insulin market - Revenue and Forecast to 2028 (US$ Million)
    - 8.1.4.1.2 US: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.1.4.1.2.1 US: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.4.1.2.2 US: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.4.1.2.3 US: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.1.4.1.2.4 US: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.1.4.1.2.5 US: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.1.4.2 Canada: Global Insulin market - Revenue and Forecast to 2028 (US$ Million)
    - 8.1.4.2.1 Canada: Insulin market - Revenue and Forecast to 2028 (US$ Million)
    - 8.1.4.2.2 Canada: Insulin Market , By Type, 2019-2028 (US$ Million)
    - 8.1.4.2.2.1 Canada: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.4.2.2.2 Canada: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.4.2.2.3 Canada: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.1.4.2.2.4 Canada: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.1.4.2.2.5 Canada: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.1.4.3 Mexico: Global Insulin market - Revenue and Forecast to 2028 (US$ Million)
    - 8.1.4.3.1 Mexico: Insulin market - Revenue and Forecast to 2028 (US$ Million)
    - 8.1.4.3.2 Mexico: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.1.4.3.2.1 Mexico: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.4.3.2.2 Mexico: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.1.4.3.2.3 Mexico: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.1.4.3.2.4 Mexico: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.1.4.3.2.5 Mexico: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
8.2 Europe: Insulin Market
- 8.2.1 Overview
- 8.2.2 Europe: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.3 Europe: Insulin Market, By Type, 2019-2028 (US$ Million)
  - 8.2.3.1 Europe: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
  - 8.2.3.2 Europe: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
  - 8.2.3.3 Europe: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
  - 8.2.3.4 Europe: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
  - 8.2.3.5 Europe: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
- 8.2.4 Europe: Insulin Market, by Country, 2021 & 2028 (%)
  - 8.2.4.1 Germany: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.1.1 Germany: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.1.2 Germany: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.2.4.1.2.1 Germany: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.1.2.2 Germany: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.1.2.3 Germany: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.2.4.1.2.4 Germany: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.2.4.1.2.5 Germany: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.2.4.2 France: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.2.1 France: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.2.2 France : Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.2.4.2.2.1 France : Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.2.2.2 France : Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.2.2.3 France : Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.2.4.2.2.4 France : Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.2.4.2.2.5 France : Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.2.4.3 UK: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.3.1 UK: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.3.2 UK: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.2.4.3.2.1 UK: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.3.2.2 UK: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.3.2.3 UK: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.2.4.3.2.4 UK: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.2.4.3.2.5 UK: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.2.4.4 Italy: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.4.1 Italy: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.4.2 Italy: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.2.4.4.2.1 Italy: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.4.2.2 Italy: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.4.2.3 Italy: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.2.4.4.2.4 Italy: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.2.4.4.2.5 Italy: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.2.4.5 Spain: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.5.1 Spain: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.5.2 Spain: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.2.4.5.2.1 Spain: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.5.2.2 Spain: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.5.2.3 Spain: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.2.4.5.2.4 Spain: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.2.4.5.2.5 Spain: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.2.4.6 Rest of Europe: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.6.1 Rest of Europe: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.2.4.6.2 Rest of Europe: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.2.4.6.2.1 Rest of Europe: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.6.2.2 Rest of Europe: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.2.4.6.2.3 Rest of Europe: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.2.4.6.2.4 Rest of Europe: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.2.4.6.2.5 Rest of Europe: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
8.3 Asia Pacific: Insulin Market
- 8.3.1 Overview
- 8.3.2 Asia Pacific: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
- 8.3.3 Asia Pacific: Insulin Market, by Type, 2019-2028 (US$ Million)
  - 8.3.3.1 Asia Pacific: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
  - 8.3.3.2 Asia Pacific: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
  - 8.3.3.3 Asia Pacific: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
  - 8.3.3.4 Asia Pacific: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
  - 8.3.3.5 Asia Pacific: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
- 8.3.4 Asia Pacific: Insulin Market, by Country, 2022 & 2028 (%)
  - 8.3.4.1 China: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.1.1 China: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.1.2 China: Insulin Market, by Type, 2019-2028 (US$ Million)
    - 8.3.4.1.2.1 China: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.3.4.1.2.2 China: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
    - 8.3.4.1.2.3 China: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.3.4.1.2.4 China: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.3.4.1.2.5 China: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.3.4.2 Japan: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.2.1 Japan: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.2.2 Japan: Insulin Market, by Type, 2019-2028 (US$ Million)
    - 8.3.4.2.2.1 Japan: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.3.4.2.2.2 Japan: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
    - 8.3.4.2.2.3 Japan: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.3.4.2.2.4 Japan: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.3.4.2.2.5 Japan: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.3.4.3 India: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.3.1 India: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.3.2 India: Insulin Market, by Type, 2019-2028 (US$ Million)
    - 8.3.4.3.2.1 India: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.3.4.3.2.2 India: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
    - 8.3.4.3.2.3 India: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.3.4.3.2.4 India: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.3.4.3.2.5 India: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.3.4.4 Australia: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.4.1 Australia: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.4.2 Australia: Insulin Market, by Type, 2019-2028 (US$ Million)
    - 8.3.4.4.2.1 Australia: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.3.4.4.2.2 Australia: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
    - 8.3.4.4.2.3 Australia: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.3.4.4.2.4 Australia: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.3.4.4.2.5 Australia: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.3.4.5 South Korea: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.5.1 South Korea: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.5.2 South Korea: Insulin Market, by Type, 2019-2028 (US$ Million)
    - 8.3.4.5.2.1 South Korea: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.3.4.5.2.2 South Korea: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
    - 8.3.4.5.2.3 South Korea: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.3.4.5.2.4 South Korea: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.3.4.5.2.5 South Korea: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.3.4.6 Rest of Asia Pacific: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.6.1 Rest of Asia Pacific: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
    - 8.3.4.6.2 Rest of Asia Pacific: Insulin Market, by Type, 2019-2028 (US$ Million)
    - 8.3.4.6.2.1 Rest of Asia Pacific: Insulin Market, by Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.3.4.6.2.2 Rest of Asia Pacific: Insulin Market, by Rapid Acting Insulins, 2019-2028 (US$ Million)
    - 8.3.4.6.2.3 Rest of Asia Pacific: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.3.4.6.2.4 Rest of Asia Pacific: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.3.4.6.2.5 Rest of Asia Pacific: Insulin Market, by Biosimilar Insulins, 2019-2028 (US$ Million)
8.4 Middle East & Africa Insulin Market Revenue and Forecasts To 2028
- 8.4.1 Overview
- 8.4.2 Middle East & Africa Insulin Market Revenue and Forecast to 2028 (US$ Million)
- 8.4.3 Middle East & Africa : Insulin Market, By Type, 2019-2028 (US$ Million)
  - 8.4.3.1 Middle East & Africa : Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
  - 8.4.3.2 Middle East & Africa : Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
  - 8.4.3.3 Middle East & Africa : Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
  - 8.4.3.4 Middle East & Africa : Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
  - 8.4.3.5 Middle East & Africa : Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
- 8.4.4 Middle East & Africa Insulin Market Revenue and Forecast to 2028, by Country (%)
  - 8.4.4.1 UAE: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.4.4.1.1 UAE: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.4.4.1.2 UAE: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.4.4.1.2.1 UAE: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.4.4.1.2.2 UAE: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.4.4.1.2.3 UAE: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.4.4.1.2.4 UAE: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.4.4.1.2.5 UAE: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.4.4.2 Saudi Arabia: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.4.4.2.1 Saudi Arabia: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.4.4.2.2 Saudi Arabia: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.4.4.2.2.1 Saudi Arabia: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.4.4.2.2.2 Saudi Arabia: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.4.4.2.2.3 Saudi Arabia: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.4.4.2.2.4 Saudi Arabia: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.4.4.2.2.5 Saudi Arabia: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.4.4.3 South Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.4.4.3.1 South Africa Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.4.4.3.2 South Africa: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.4.4.3.2.1 South Africa: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.4.4.3.2.2 South Africa: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.4.4.3.2.3 South Africa: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.4.4.3.2.4 South Africa: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.4.4.3.2.5 South Africa: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.4.4.4 Rest of Middle East & Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.4.4.4.1 Rest of Middle East & Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
    - 8.4.4.4.2 Rest of Middle East & Africa: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.4.4.4.2.1 Rest of Middle East & Africa: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.4.4.4.2.2 Rest of Middle East & Africa: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.4.4.4.2.3 Rest of Middle East & Africa: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.4.4.4.2.4 Rest of Middle East & Africa: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.4.4.4.2.5 Rest of Middle East & Africa: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
8.5 South and Central America Insulin Market Revenue and Forecasts To 2028
- 8.5.1 Overview
- 8.5.2 South and Central America: Insulin Market - Revenue and Forecast to 2028 (USD Million)
- 8.5.3 South and Central America: Insulin Market, By Type, 2019-2028 (US$ Million)
  - 8.5.3.1 South and Central America: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
  - 8.5.3.2 South and Central America: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
  - 8.5.3.3 South and Central America: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
  - 8.5.3.4 South and Central America: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
  - 8.5.3.5 South and Central America: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
- 8.5.4 South and Central America Insulin Market Revenue and Forecast to 2028, by Country (%)
  - 8.5.4.1 Brazil: Insulin Market - Revenue and Forecast to 2028 (USD Million)
    - 8.5.4.1.1 Brazil: Insulin Market - Revenue and Forecast to 2028 (USD Million)
    - 8.5.4.1.2 Brazil: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.5.4.1.2.1 Brazil: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.5.4.1.2.2 Brazil: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.5.4.1.2.3 Brazil: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.5.4.1.2.4 Brazil: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.5.4.1.2.5 Brazil: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.5.4.2 Argentina: Insulin Market - Revenue and Forecast to 2028 (USD Million)
    - 8.5.4.2.1 Argentina: Insulin Market - Revenue and Forecast to 2028 (USD Million)
    - 8.5.4.2.2 Argentina: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.5.4.2.2.1 Argentina: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.5.4.2.2.2 Argentina: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.5.4.2.2.3 Argentina: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.5.4.2.2.4 Argentina: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.5.4.2.2.5 Argentina: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
  - 8.5.4.3 Rest of South and Central America: Insulin Market - Revenue and Forecast to 2028 (USD Million)
    - 8.5.4.3.1 Rest of South and Central America: Insulin Market - Revenue and Forecast to 2028 (USD Million)
    - 8.5.4.3.2 Rest of South and Central America: Insulin Market, By Type, 2019-2028 (US$ Million)
    - 8.5.4.3.2.1 Rest of South and Central America: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
    - 8.5.4.3.2.2 Rest of South and Central America: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
    - 8.5.4.3.2.3 Rest of South and Central America: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
    - 8.5.4.3.2.4 Rest of South and Central America: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
    - 8.5.4.3.2.5 Rest of South and Central America: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)

9. Impact of COVID-19 Pandemic on Global Insulin Market

9.1 North America: Impact Assessment of COVID-19 Pandemic
9.2 Europe: Impact Assessment of COVID-19 Pandemic
9.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
9.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
9.5 South and Central America: Impact Assessment of COVID-19 Pandemic

10. Insulin Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Insulin Market (%)
10.3 Organic Developments
- 10.3.1 Overview
10.4 Inorganic Developments
- 10.4.1 Overview

11. Company Profile

11.1 Eli Lilly and Company
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Novo Nordisk A/S
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Biocon
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 WOCKHARDT
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Adocia
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 GlaxoSmithKline plc.
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Sanofi
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Pfizer Inc.
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Merck & Co., Inc.
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 Tonghua Dongbao Pharmaceutical Co., Ltd.
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments
11.11 BIGFOOT BIOMEDICAL, INC.
- 11.11.1 Key Facts
- 11.11.2 Business Description
- 11.11.3 Products and Services
- 11.11.4 Financial Overview
- 11.11.5 SWOT Analysis
- 11.11.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms